Drug Profile


Alternative Names: Ibaconda; Olsalazine/colchicine

Latest Information Update: 15 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centre for Digestive Diseases
  • Developer Giaconda
  • Class Colchicum alkaloids; Salicylates
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 04 Jun 2009 Retrospective analysis data from a phase I study in constipation-predominant Irritable bowel syndrome presented at the Digestive Disease Week 2009 (DDW-2009)
  • 31 Jul 2007 Phase-I clinical trials in Irritable bowel syndrome in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top